Skip to main content

GLPG

Stock
Health Care
Biotechnology

Performance overview

GLPG Price
Price Chart

Forward-looking statistics

Beta
0.79
Risk
31.94%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.

Company info

SectorHealth Care
IndustryBiotechnology
Employees975
Market cap$1.8B

Fundamentals

Enterprise value-$1.7B
Revenue$338.8M
Revenue per employee
Profit margin-58.83%
Debt to equity0.40

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$3.22
Dividend per share
Revenue per share$0.22
Avg trading volume (30 day)$8M
Avg trading volume (10 day)$6M
Put-call ratio

Macro factor sensitivity

Growth-0.1
Credit+2.4
Liquidity-0.3
Inflation-1.6
Commodities-0.7
Interest Rates-1.5

Valuation

Dividend yield0.00%
PEG Ratio-27.72
Price to sales6.63
P/E Ratio-27.72
Enterprise Value to Revenue-5.01
Price to book0.69

Upcoming events

Next earnings dayOctober 31, 2024
Next dividend day
Ex. dividend day

News

Galapagos (GLPG) Loses -21.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Galapagos (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Investment Research (February 5, 2025)
Galapagos To Spin Off Innovative Medicines Business

On January 8, 2025, Galapagos NV. (US Nasdaq ADR: GLPG; $23.76, Market Capitalization: $1.56 billion), announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on innovative medicines. The SpinCo will be focused on building a pipeline of innovative medicines with robust clinical proof-of-concept in oncology, immunology, and/or virology through strategic business development transactions.

Forbes (January 21, 2025)
Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients

Galapagos NV (NASDAQ: GLPG) announced results of two post-hoc analyses from the SELECTION and SELECTION LTE studies of filgotinib for active ulcerative colitis (UC).  The analyses showed clinical benefits of continued dosing with filgotinib 200mg, an oral once-daily JAK1 preferential inhibitor, in patients who did not respond at week 10.

Benzinga (October 5, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free